MAIA Biotechnology Ends At-the-Market Stock Program
MAIA Biotechnology, Inc. has suspended sales of its common stock under its At The Market Offering Agreement with H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
MAIA Biotechnology, Inc. has suspended sales of its common stock under its At The Market Offering Agreement with H.C. Wainwright & Co. and has given notice to terminate the agreement effective seven business days after May 14, 2026.
Under a March 28, 2025 prospectus supplement for up to $11,200,000, the company offered and sold 3,116,012 shares of common stock, generating gross proceeds of approximately $5,680,924 before ending use of this at-the-market program.
8-K Event Classification
Item 1.02 — Termination of a Material Definitive Agreement
1 item
Item 1.02
Termination of a Material Definitive Agreement
Business
A significant contract was terminated, which may affect business operations or revenue.
Key Figures
ATM program capacity: $11,200,000
Shares sold under ATM: 3,116,012 shares
Gross proceeds from ATM: $5,680,924
+1 more
4 metrics
ATM program capacity
$11,200,000
Prospectus supplement dated March 28, 2025
Shares sold under ATM
3,116,012 shares
Common stock sold pursuant to sales agreement
Gross proceeds from ATM
$5,680,924
Approximate gross proceeds from ATM share sales
Termination effective period
7 business days
Effective after May 14, 2026 notice
Key Terms
At The Market Offering Agreement, prospectus supplement, gross proceeds, emerging growth company
4 terms
At The Market Offering Agreement financial
"suspended sales of its common stock, par value $0.0001 per share (“Common Stock”), pursuant to that certain At The Market Offering Agreement dated February 14, 2024"
An at-the-market offering agreement is a contract that lets a company sell newly issued shares directly into the open market through a broker, at whatever price the stock is trading at that moment. For investors this matters because it can increase the number of shares available (which may dilute existing ownership) while providing a flexible, often faster way for the company to raise cash without fixing a price, similar to a vendor selling small batches at current market stalls rather than setting a single fixed price.
prospectus supplement regulatory
"Since filing of the March 28, 2025 prospectus supplement for up to $11,200,000 under the sales agreement"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
gross proceeds financial
"we have offered and sold 3,116,012 shares of common stock for gross proceeds of approximately $5,680,924"
The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.
emerging growth company regulatory
"405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did MAIA (MAIA) disclose about its at-the-market offering?
MAIA Biotechnology suspended sales of common stock under its At The Market Offering Agreement with H.C. Wainwright & Co. and notified the agent it will terminate the agreement, with termination becoming effective seven business days after May 14, 2026.
How much stock did MAIA (MAIA) sell through its ATM program?
MAIA Biotechnology sold 3,116,012 shares of common stock through its at-the-market program. These shares were issued under a prospectus supplement tied to the sales agreement with H.C. Wainwright & Co., generating several million dollars in gross proceeds for the company.
What were MAIA (MAIA) gross proceeds from the ATM stock sales?
MAIA Biotechnology reported gross proceeds of approximately $5,680,924 from shares sold under its At The Market Offering Agreement. These proceeds came from issuing millions of common shares pursuant to a prospectus supplement associated with the program before MAIA decided to suspend and terminate it.
What was the maximum amount MAIA (MAIA) could offer under the ATM prospectus?
The prospectus supplement dated March 28, 2025 permitted MAIA Biotechnology to offer up to $11,200,000 of common stock under the sales agreement. The company used this capacity to sell over three million shares before later suspending sales and initiating termination of the agreement.
When does MAIA (MAIA) termination of the ATM agreement become effective?
MAIA Biotechnology’s termination of its At The Market Offering Agreement becomes effective seven business days after May 14, 2026. The company has already suspended additional sales under the agreement and formally notified H.C. Wainwright & Co., the sales agent, in line with the agreement’s terms.
Who was MAIA (MAIA) sales agent for the ATM offering?
H.C. Wainwright & Co., LLC served as MAIA Biotechnology’s sales agent under the At The Market Offering Agreement. The firm handled sales of MAIA’s common stock pursuant to the March 28, 2025 prospectus supplement until MAIA suspended sales and moved to terminate the agreement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates